[go: up one dir, main page]

MX2021008044A - Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2. - Google Patents

Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.

Info

Publication number
MX2021008044A
MX2021008044A MX2021008044A MX2021008044A MX2021008044A MX 2021008044 A MX2021008044 A MX 2021008044A MX 2021008044 A MX2021008044 A MX 2021008044A MX 2021008044 A MX2021008044 A MX 2021008044A MX 2021008044 A MX2021008044 A MX 2021008044A
Authority
MX
Mexico
Prior art keywords
masp
complement activation
dependent complement
methods
dependent
Prior art date
Application number
MX2021008044A
Other languages
English (en)
Inventor
Thomas Dudler
Gregory A Demopulos
Hans-Wilhelm Schwaeble
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of MX2021008044A publication Critical patent/MX2021008044A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)

Abstract

En un aspecto, la invención proporciona métodos de inhibición de los efectos de la activación del complemento dependiente de MASP-2 en un sujeto vivo que sufre de, o en riesgo de desarrollar una microangiopatía trombótica (TMA). Los métodos comprenden el paso de administrar, a un sujeto en necesidad del mismo, una cantidad de un agente inhibidor de MASP-2 efectiva para inhibir la activación del complemento dependiente de MASP-2. En algunas modalidades, el agente inhibidor de MASP-2 inhibe la lesión celular asociada a MASP-2 mediada por activación de la vía alternativa del complemento, mientras que deja la Vía clásica (dependiente de C1q) del a clásica del sistema inmune intacto.
MX2021008044A 2013-10-17 2016-04-18 Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2. MX2021008044A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361892283P 2013-10-17 2013-10-17
US201462020845P 2014-07-03 2014-07-03

Publications (1)

Publication Number Publication Date
MX2021008044A true MX2021008044A (es) 2021-10-13

Family

ID=52828769

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016005017A MX2016005017A (es) 2013-10-17 2014-10-17 Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.
MX2021008044A MX2021008044A (es) 2013-10-17 2016-04-18 Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016005017A MX2016005017A (es) 2013-10-17 2014-10-17 Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.

Country Status (25)

Country Link
US (3) US20150166675A1 (es)
EP (2) EP3057993B1 (es)
JP (3) JP2016539919A (es)
KR (3) KR20160062186A (es)
CN (2) CN111588855A (es)
AU (2) AU2014337047B2 (es)
BR (1) BR112016008409B1 (es)
CA (1) CA2926385A1 (es)
CL (2) CL2016000908A1 (es)
CY (1) CY1123776T1 (es)
DK (1) DK3057993T3 (es)
ES (1) ES2829913T3 (es)
HR (1) HRP20201733T1 (es)
HU (1) HUE051746T2 (es)
IL (2) IL283373B2 (es)
LT (1) LT3057993T (es)
MX (2) MX2016005017A (es)
NZ (2) NZ757986A (es)
PL (1) PL3057993T3 (es)
PT (1) PT3057993T (es)
RS (1) RS61351B1 (es)
RU (1) RU2718850C2 (es)
SI (1) SI3057993T1 (es)
SM (1) SMT202000659T1 (es)
WO (1) WO2015058143A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
MX355648B (es) 2011-04-08 2018-04-26 Univ Leicester El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2.
RS61351B1 (sr) 2013-10-17 2021-02-26 Omeros Corp Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2
BR112018009311A8 (pt) 2015-11-09 2019-02-26 Omeros Corporation E Univ Of Leicester ?método para tratar um sujeito humano sofrendo de tma persistente associada com transplante de célula tronco hematopoiética?
KR102564616B1 (ko) * 2016-01-05 2023-08-08 유니버시티 오브 레스터 필요로 하는 대상체에서 섬유증의 억제 방법
CN109152834A (zh) * 2016-03-31 2019-01-04 奥默罗斯公司 抑制有需要的受试者的血管发生的方法
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
JOP20190068A1 (ar) * 2016-10-13 2019-04-01 Omeros Corp طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي
TWI818919B (zh) * 2017-08-15 2023-10-21 美商歐米諾斯公司 用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法
EP3672994A4 (en) * 2017-08-25 2021-06-02 Omeros Corporation HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITIVE ANTIBODY FORMULATIONS, KITS, AND METHODS FOR TREATING PEOPLE WITH ATYPICAL HEMOLYTIC SYNDROME
CN108171772B (zh) * 2017-12-28 2021-11-19 中国地质调查局西安地质调查中心 利用mapGIS、CJKCOOR_Ver和DELF3D提取河流边界的方法
CN119350433A (zh) 2018-05-29 2025-01-24 奥默罗斯公司 Masp-2抑制剂和使用方法
US20200140570A1 (en) * 2018-06-22 2020-05-07 Omeros Corporation Compositions and Methods of Inhibiting MASP-2 for the Treatment of Various Thrombotic Diseases and Disorders
JP7110491B2 (ja) * 2018-12-13 2022-08-01 アルジェニクス ビーブイ ヒト補体因子ｃ２ｂに対する抗体及び使用方法
CN111134250A (zh) * 2019-12-03 2020-05-12 海南大学 一种草地贪夜蛾幼虫食用人工饲料的配方和制作方法
BR112022010881A2 (pt) 2019-12-04 2022-08-23 Omeros Corp Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado a serina protease-2 associada à lectina de ligação ao manan
US12030853B2 (en) 2019-12-04 2024-07-09 Omeros Corporation MASP-2 inhibitors and methods of use
IL293588A (en) 2019-12-04 2022-08-01 Omeros Corp Masp-2 inhibitor compounds, compositions comprising same and uses thereof
KR20220110530A (ko) 2019-12-04 2022-08-08 오메로스 코포레이션 Masp-2 억제자 및 사용 방법
CN115215937B (zh) * 2021-04-15 2023-05-26 上海麦济生物技术有限公司 抗人masp-2抗体及其制备方法和应用
CN115300608B (zh) * 2021-05-06 2023-06-02 四川大学 一种利用甘露糖结合凝集素阻断新冠病毒感染的方法
US20230265215A1 (en) 2021-12-10 2023-08-24 Omeros Corporation Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
US20240228499A1 (en) 2022-11-30 2024-07-11 Omeros Corporation Masp-2 inhibitors and methods of use
CN119143861B (zh) * 2024-11-19 2025-01-24 四川大学 一种甘露聚糖结合凝集素改造蛋白ppg-rep-MBL、DNA分子、表达载体、宿主细胞，以及用途

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4526909A (en) 1984-01-09 1985-07-02 Regents Of The University Of California Polymethylmethacrylate delivery system for bone morphogenetic protein
US4563489A (en) 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
JPH0662679B2 (ja) 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
RO114469B1 (ro) 1987-12-15 1999-04-30 Gene Shears Pty Ltd Compus oligoribonucleotidic, procedeu de preparare si metoda de inactivare
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
EP0438803B1 (en) 1990-01-26 1997-03-12 Immunomedics, Inc. Vaccines against cancer and infectious diseases
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
AU4467396A (en) 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
RU2271825C2 (ru) 1999-07-21 2006-03-20 Омерос Корпорейшн Растворы и способы ингибирования боли, воспаления и разрушения хряща
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
KR20040094413A (ko) 2002-02-01 2004-11-09 오메로스 코포레이션 연골 분해를 전신 억제하기 위한 조성물 및 방법
WO2004009664A2 (en) 2002-07-19 2004-01-29 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
PT2374819T (pt) * 2003-05-12 2017-07-04 Helion Biotech Aps Anticorpos para masp-2
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20130266559A1 (en) * 2004-06-10 2013-10-10 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
EP2446902A1 (en) * 2004-06-10 2012-05-02 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2352517A4 (en) * 2008-11-10 2013-01-16 Alexion Pharma Inc METHOD AND COMPOSITIONS FOR TREATING COMPLEMENT ASSOCIATED ILLNESSES
CN102712687A (zh) 2009-07-17 2012-10-03 丹麦国家医院 作为补体激活的抑制剂的masp同种型
PT2488203T (pt) 2009-10-16 2017-03-10 Univ Leicester Métodos para tratamento de coagulação intravascular disseminada através da inibição da activação do complemento dependente de masp-2
JP5852021B2 (ja) 2010-03-01 2016-02-03 アレクシオン ファーマシューティカルズ， インコーポレイテッド ドゴー病を処置するための方法および組成物
US20150166676A1 (en) 2011-04-08 2015-06-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
MX355648B (es) * 2011-04-08 2018-04-26 Univ Leicester El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2.
RS60541B1 (sr) 2011-05-04 2020-08-31 Omeros Corp Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa
JP2013030593A (ja) 2011-07-28 2013-02-07 J Devices:Kk 半導体装置、該半導体装置を垂直に積層した半導体モジュール構造及びその製造方法
IN2015KN00015A (es) 2012-06-18 2015-07-31 Omeros Corp
AU2013334229B2 (en) 2012-10-25 2018-02-15 Bioverativ Usa Inc. Anti-complement C1s antibodies and uses thereof
CA2921856A1 (en) 2013-09-16 2015-03-19 Children's Hospital Medical Center Compositions and methods for treatment of hsct-associated thrombotic microangiopathy
RS61351B1 (sr) 2013-10-17 2021-02-26 Omeros Corp Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2
BR112018009311A8 (pt) 2015-11-09 2019-02-26 Omeros Corporation E Univ Of Leicester ?método para tratar um sujeito humano sofrendo de tma persistente associada com transplante de célula tronco hematopoiética?

Also Published As

Publication number Publication date
CL2016000908A1 (es) 2016-12-02
SMT202000659T1 (it) 2021-01-05
BR112016008409A2 (pt) 2017-10-03
IL283373B2 (en) 2024-08-01
EP3750919A1 (en) 2020-12-16
KR20220053057A (ko) 2022-04-28
KR20240101700A (ko) 2024-07-02
EP3057993B1 (en) 2020-08-12
RS61351B1 (sr) 2021-02-26
IL245115A0 (en) 2016-06-30
SI3057993T1 (sl) 2021-03-31
US20150166675A1 (en) 2015-06-18
RU2016118769A3 (es) 2018-11-21
MX2016005017A (es) 2016-11-07
NZ757986A (en) 2022-07-29
IL283373A (en) 2021-07-29
JP2016539919A (ja) 2016-12-22
JP6953498B2 (ja) 2021-10-27
ES2829913T3 (es) 2021-06-02
WO2015058143A1 (en) 2015-04-23
EP3057993A4 (en) 2017-09-13
JP2022000467A (ja) 2022-01-04
IL283373B1 (en) 2024-04-01
PL3057993T3 (pl) 2021-02-08
PT3057993T (pt) 2020-11-19
NZ719476A (en) 2022-07-29
LT3057993T (lt) 2020-11-25
CN105683219A (zh) 2016-06-15
EP3057993A1 (en) 2016-08-24
RU2718850C2 (ru) 2020-04-15
AU2020203748A1 (en) 2020-06-25
US20240124611A1 (en) 2024-04-18
HUE051746T2 (hu) 2021-03-29
AU2014337047A1 (en) 2016-05-19
HRP20201733T1 (hr) 2021-02-05
CN105683219B (zh) 2020-07-14
CA2926385A1 (en) 2015-04-23
JP2020037568A (ja) 2020-03-12
KR102744762B1 (ko) 2024-12-20
BR112016008409B1 (pt) 2021-06-15
AU2014337047B2 (en) 2020-03-12
CN111588855A (zh) 2020-08-28
AU2020203748B2 (en) 2022-08-04
KR20160062186A (ko) 2016-06-01
DK3057993T3 (en) 2020-11-16
RU2016118769A (ru) 2017-11-22
RU2020111211A (ru) 2021-11-08
JP7397037B2 (ja) 2023-12-12
CL2018001557A1 (es) 2018-07-20
US20200157244A1 (en) 2020-05-21
CY1123776T1 (el) 2022-03-24
KR102677379B1 (ko) 2024-06-24
IL245115B (en) 2022-05-01
US11525011B2 (en) 2022-12-13

Similar Documents

Publication Publication Date Title
MX2021008044A (es) Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.
PH12018501009A1 (en) Methods for treating conditions associated with masp-2 dependent complement activation
MX2024010937A (es) Metodos para la inhibicion de fibrosis en un sujeto en necesidad del mismo.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX381987B (es) El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX378686B (es) Composiciones que comprenden cepas bacterianas.
MX2021014709A (es) Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes.
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MX2021002406A (es) Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica.
MX2018003472A (es) Moduladores de la expresion de kras.
MX2020011772A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2019004500A (es) Terapia de combinación para la inhibición de componente de complemeto (c3).
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
MX2019000088A (es) Composiciones y metodos para detectar y tratar la diabetes.
CR20170259A (es) Terapias de envenenamiento y composiciones farmacéuticas, sistemas y equipos relacionados
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
MX2021006326A (es) Inhibidores de pcna.
PH12017501864A1 (en) Compositions and methods for treating autism
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
BR112016012248A2 (pt) método de tratamento de nefropatia
JOP20140008B1 (ar) استخدام العوامل المساعدة لمستقبل ألفا 7 أسيتيل كولين نيكوتينية
MX2015012164A (es) Métodos de tratamiento de enfermedad renal y otros trastornos.
NZ711523A (en) Use of sedoheptulose for prevention or treatment of inflammation